Clinical Roundup

Lifileucel shrinks tumors in mNSCLC in phase II trial

Researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute said results of a phase II, multi-center clinical trial revealed that a new type of cell therapy is a promising potential treatment option for patients with stage 4 lung cancer who were previously treated but later developed resistance to other therapies.
In Brief

OSU—James Immunotherapy Management Clinic to focus on managing immune side effects and cancer control

A clinic at The Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer Hospital and Richard J. Solove Research Institute and Pelotonia Immuno-Oncology Institute aims to help manage the autoimmune side effects of immunotherapy-based cancer treatment and allow patients to live the fullest life possible both during cancer treatment and long-term as a survivor.
In Brief

Nationwide Children’s Hospital and OSUCCC—James open proton therapy center opens

Nationwide Children’s Hospital and The Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer Hospital and Richard J. Solove Research Institute opened a $100 million, 55,000 square foot proton therapy center. It is the first treatment facility in central Ohio offering this highly targeted form of radiation therapy for treatment of complex tumors that cannot be removed through surgery.